Vivek Subbiah Receives 2024 Yvonne Award in the Voice of Oncology Category

Yvonne Award Winners 2024 by OncoDaily

We are excited to announce the esteemed winners of the Yvonne Award by OncoDaily, designed to recognize young innovators and leaders advancing cancer care.

Yvonne Award in the Voice of Oncology category is presented to Dr. Vivek Subbiah. The OncoDaily team extends their heartfelt congratulations and sincere gratitude to Dr. Subbiah for his exceptional communication and advocacy, significantly improving cancer care awareness and understanding globally.

The Voice of Oncology Award, presented by OncoDaily, recognizes individuals who have significantly influenced the field through their outspoken advocacy and contributions. This award is given to those whose work and insights have been widely acknowledged and cited within the oncology community.

Recipients of this award are celebrated for raising awareness, shaping public opinion, and driving conversations that lead to meaningful improvements in cancer care. Their voices have not only been heard but have also served as a catalyst for change and progress in oncology.

About Vivek Subbiah

Dr. Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (SCRI). He manages SCRI’s nine drug development units and drives the expansion of early-phase clinical trials and programs across SCRI’s network, which includes over 1,300 physicians at more than 250 locations in 24 states.

Before joining SCRI, Dr. Subbiah worked at the University of Texas MD Anderson Cancer Center for nearly 15 years. He held roles such as Executive Director of Medical Oncology Research for the MD Anderson Cancer Network and Clinical Medical Director for the Division of Cancer Medicine, overseeing clinical care delivery for the Phase I program.

Dr. Subbiah has led over 100 phase I/II trials as the principal investigator and participated as a co-investigator in over 200 clinical trials. He is known for his leadership in studies that have led to FDA, European Medicines Agency, and other international regulatory approvals. Specializing in tumor-agnostic precision oncology, Dr. Subbiah played a crucial role in obtaining FDA approval for BRAF and RET tissue-agnostic therapies.

He has published over 400 peer-reviewed articles in high-impact journals such as The New England Journal of Medicine, Nature Medicine, Journal of Clinical Oncology, JAMA Oncology, Cancer Discovery, Lancet Oncology, Nature Reviews Clinical Oncology, Lancet Diabetes and Endocrinology, and Clinical Cancer Research.

Dr. Subbiah is a member of the ESMO Translational Research and Precision Medicine Working Group and serves on the Editorial Board of Annals of Oncology.